Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW. Afghahi A, et al. Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26. Clin Cancer Res. 2018. PMID: 29581131 Free PMC article.
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Caswell-Jin JL, et al. Among authors: curtis c. Nat Commun. 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. Nat Commun. 2019. PMID: 30737380 Free PMC article.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C. Rueda OM, et al. Among authors: curtis c. Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13. Nature. 2019. PMID: 30867590 Free PMC article.
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Caswell-Jin JL, et al. Among authors: curtis c. Nat Commun. 2019 May 30;10(1):2433. doi: 10.1038/s41467-019-10456-x. Nat Commun. 2019. PMID: 31147552 Free PMC article.
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ. Hurvitz SA, et al. Among authors: curtis c. Nat Commun. 2020 Nov 17;11(1):5824. doi: 10.1038/s41467-020-19494-2. Nat Commun. 2020. PMID: 33203854 Free PMC article. Clinical Trial.
1,195 results